Given the widespread overexpression of APLP2 observed not only in pancreatic cancer but also in colon, breast, prostate, and lung cancers [77,78], TBO could exhibit a global anti-tumor effect through the inhibition of APLP2/CTFs. Here, APLP2 is linked to familial pancreatic carcinoma.